CAGE Bio

Focus: CAGE Bio is a pre-clinical to early-stage biotech company leveraging Deep Eutectic Ionic Liquids (DEIL) platform technology for topical therapeutic delivery, with a focus on dermatology indications. Founded in 2020 and based in San Carlos, CA, the company is in early development stages with multiple Phase 1–2 programs.

Oncology

Profile data last refreshed 10h ago · AI intelligence enriched 2w ago

Open Jobs

About CAGE Bio

AI assessmentNot Hiring

No open roles listed right now. Follow CAGE Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CB-0002B

Erythema

N/A

CGB-400 Topical Gel

Fungal Infection

N/A

CGB-400

Rosacea

Help build intelligence for CAGE Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to differentiated platform technology (DEIL) that could enable competitive advantages in topical drug delivery across dermatology and beyond.
Early-stage company offers potential for significant equity upside and hands-on responsibility across R&D functions during critical clinical validation phase.
Multi-indication pipeline (rosacea, atopic dermatitis, vitiligo, fungal infection, erythema) provides breadth of therapeutic learning.

Watch Out For

Currently zero active job listings and no hiring data signal; company appears to be in early stage with minimal headcount expansion announced.
No published financial data (funding, revenue, cash position) available; pre-revenue status and funding sources are opaque, creating significant cash-runway risk.
Early-stage pipeline with zero active trials reported and all programs in Phase 1–2; clinical validation, regulatory pathway, and go-to-market strategy remain unproven.

CAGE Bio

About CAGE Bio

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (0)